Jacobs ML, Verhoog S, van der Linden WH, Huisman WM, Wallenburg HC, Weber RF. Glucagon stimulation test: assessment of beta-cell function in gestational diabetes mellitus.
Eur J Obstet Gynecol Reprod Biol 1994;
56:27-30. [PMID:
7982513 DOI:
10.1016/0028-2243(94)90149-x]
[Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
OBJECTIVE
Because women with gestational diabetes mellitus have a risk of up to 60% for the later development of type II diabetes, we used the intravenous glucagon stimulation test to evaluate beta-cell function in pregnant women.
PATIENTS
Twenty-seven pregnant women with one or more risk factors for gestational diabetes had an intravenous beta-cell stimulation test. Glucose, C-peptide and insulin levels were measured at baseline and 5, 10 and 15 min after the administration of 1 mg glucagon. The women were classified using the 75-g oral glucose tolerance test according to World Health Organization criteria. During the oral glucose tolerance test glucose, C-peptide and insulin levels were measured at baseline and at 2 h.
RESULTS
Insulin and C-peptide responses were significantly lower in pregnant women with impaired glucose tolerance and diabetes compared with women with normal glucose tolerance.
CONCLUSION
This study shows gradually decreasing insulin secretion from normal to subnormal in pregnant women without and with glucose intolerance, and diabetes mellitus, respectively.
Collapse